MSD has been conducting a Phase 3 trial since this May combining intismeran autogene, a messenger RNA (mRNA)-based personalized cancer vaccine, with Keytruda Qlex in patients with non-small cell lung cancer. The study compares the combination with intismeran monotherapy and a placebo in stage 1 patients, following results from MSD and Moderna showing the efficacy of an intravenous Keytruda formulation combined with intismeran autogene. If the combination produces a meaningful treatment effect and reaches commercialization, Alteogen's revenue would also increase. Samyang Biopharm published preclinical results for NanoReady, a nanoparticle gene-delivery platform designed to deliver mRNA selectively to immune-function cells, as a cover article in an international academic journal. GI Innovation is conducting a Phase 2 trial of GI-102, an immuno-oncology candidate based on Keytruda and interleukin-2 that activates T cells and natural killer cells. The companies' developments reflect the need for delivery systems and immune boosters that can strengthen responses to patient-specific tumor mutations.